Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;3(2):128-31.
doi: 10.1158/1940-6207.CAPR-09-0268. Epub 2010 Jan 26.

Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung

Eva Szabo  1
Affiliations
Review

Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung

Eva Szabo. Cancer Prev Res (Phila). 2010 Feb.

Abstract

This perspective on Kim et al. (beginning on p. 148 in this issue of the journal) examines the value of the Ki-67 proliferation index as a surrogate end point in early-phase clinical lung cancer prevention trials. The clinical trial of Kim et al. shows an effect of the cyclooxygenase-2-selective inhibitor celecoxib at a high dose on Ki-67 expression in the normal bronchial epithelia of current and former smokers. The critical issue of how these data can be used to further drug development is discussed.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Comment on

References

    1. Szabo E. Selecting targets for cancer prevention: Where do we go from here? Nat Rev Cancer. 2006;6:867–74. - PubMed
    1. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nature Rev. 2002;2:1–9. - PubMed
    1. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst. 1990;82:555–60. - PubMed
    1. Szabo E. Assessing efficacy in early-phase cancer prevention trials: The case of oral premalignancy. Cancer Prev Res. 2009;1:312–315. - PubMed
    1. Kim ES, Hong WK, Lee JJ, et al. Biologic activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res. 2010;3 - PMC - PubMed

MeSH terms